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Summary 
Interactions between products of the mouse W  locus, which encodes the c-kit tyrosine kinase 
receptor, and the SI locus, which encodes a ligand for c-kit receptor, which we have designated 
stem cell factor (SCF), have a critical role in the development of mast cells. Mice homozygous 
for mutations at either locus exhibit several phenotypic abnormalities including a virtual absence 
of mast cells.  Moreover,  the c-kit ligand  SCF can induce the proliferation  and maturation  of 
normal  mast cells in vitro or in vivo, and also can result in repair  of the mast cell deficiency 
of S1/SI  a mice in vivo. We now report that administration  of SCF intradermally in vivo results 
in dermal mast cell activation and a mast cell-dependent acute inflammatory response. This effect 
is c-kit receptor dependent, in that it is not observed when SCF is administered to mice containing 
dermal mast cells expressing functionally inactive c-kit receptors, is observed with both glycosylated 
and nonglycosylated forms of SCF, and occurs at doses of SCF at least 10-fold lower on a molar 
basis than the minimally effective dose of the classical dermal mast cell-activating agent substance 
P. These findings represent the first demonstration in vivo that a c-kit ligand can result in the 
functional activation of any cellular lineage expressing the c-kit receptor, and suggest that interactions 
between the c-kit receptor and its ligand may influence mast cell biology through complex effects 
on proliferation,  maturation,  and function. 
S 
everal lines of evidence indicate that interactions between 
the c-kit tyrosine kinase receptor and its ligand critically 
regulate mouse mast cell development (reviewed in references 
1-3). Mice with a double dose of mutant genes at either the 
W/c-kit locus on chromosome 5 or the Sl locus on chromo- 
some 10, which encodes a ligand for the c-kit receptor that 
has  been  named  stem  cell  factor  (SCF) 1 (4-6),  mast  cell 
growth factor (7-9),  kit ligand  (10),  and Steel factor (11), 
are virtually devoid of mature mast cells (reviewed in refer- 
ences 1 and 12).  Recombinant forms of the c-kit ligand in- 
duce proliferation  of in vitro-derived immature IL,3-dependent 
mast cells (4,  5,  7,  9) or mature  mast  cells  purified from 
1  Abbreviations used in thispaper: BMCMC, IL-3-dependent,  bone marrow- 
derived cultured mast cells; CHO, Chinese hamster ovary cell; CTMC, 
connective tissue type mast cell(s); DNP30-40  HSA, DNP human serum 
albumin; 12SI-GPF, ~I-guinea pig fibrinogen; rrSCF  164, recombinant rat 
stem cell factor~4; SCF, stem cell factor. 
the peritoneal cavity of mice (3).  Recombinant rat SCF 164 
(rrSCF164), representing the soluble form of the c-kit ligand, 
secreted by a Buffalo rat liver cell line (4-6), not only induces 
proliferation of immature or mature mouse mast cells in vitro 
(3, 4), but also promotes the maturation of IL-3-dependent, 
bone marrow-derived cultured mouse mast cells (BMCMC) 
in vitro (3) and induces the proliferation and maturation of 
mouse or rat mast cells when administered in vivo (2). Ad- 
ministration  of rrSCF 164 in vivo also can repair the macro- 
c/tic anemia and the mast cell deficiency expressed by Sl/Sl a 
mice (2,  6). 
The effects of rrSCF 164 on mouse or rat mast cell prolifer- 
ation and maturation,  when taken together with  the pro- 
found mast cell defidendes expressed by W or SI mutant mice, 
indicate that interactions between the c-kit receptor and its 
ligand importantly regulate normal mast cell development. 
However, certain other hematopoietic growth factors, in ad- 
dition to regulating the proliferation of cells that express the 
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tional activity of their target cells. For example, IL-3 represents 
a major growth factor for human basophils (13, 14), but also 
both can function as an agonist that induces basophils to re- 
lease histamine and other mediators, and can enhance the ability 
of basophils to release mediators in response to other secreta= 
gogues  (15-20). 
We have reported that rrSCF 164 can induce the release of 
serotonin (5-hydroxytryptamine) from BMCMC in vitro, but 
the magnitude of serotonin release is modest, and mediator 
release is observed only at concentrations of rrSCF 164 at least 
10-fold higher than those that can induce proliferation of these 
cells (21). However, different populations of mast cells can 
express multiple differences in phenotype, notably including 
variation in their sensitivity to the same agonists of mediator 
release (reviewed in reference 22).  Moreover, certain agents 
that are relatively weak agonists of mast cell mediator release 
in vitro, such as PMA, represent potent stimuli of mast cell 
mediator release in vivo (23). We therefore investigated the 
ability  of rrSCF 164  to  induce  dermal  mast  cell  activation 
when injected into the skin of mice in vivo, using approaches 
that permitted us to test dermal mast cells expressing either 
normal or functionally inactive forms of the c-kit receptor. 
Our results clearly indicate that rrSCF 164 represents a potent 
agonist  of dermal mast cell activation,  and show that  this 
effect of rrSCF 164 requires that the mast cells express a func- 
tionally active c-kit receptor. 
Materials and Methods 
Recombinant SCE  Recombinant  rat  SCF 164  (rrSCF 164) vcas 
purified from either Escherichia coli (E. coti-SCF) or Chinese ham- 
ster ovary cells (CHO-SCF) (5, 6). In some experiments, we used 
E. coli-derived rrSCF  164 that had been modified by the covalent at- 
tachment of polyethylene glycol (6). The various forms of rrSCF  164 
were kept as stock solutions at 4~  in PBS and were diluted for 
intradermalinjection in Hanks' MEM (HMEM) containing pipera- 
zine-N,N'bis[2-ethane sulfonic acid] (HMEM/Pipes)just before 
use (24). Similar dilutions of PBS alone in HMEM/Pipes were used 
for control injections. In most experiments, the left ears received 
injections of rrSCF  1~4 in 0.02-ml volumes (challenged ears), where- 
as the right ears received 0.02 ml of the vehicle  (control ears). 
E. coli-derived rrSCF  164 was used for the most of our experiments. 
According to the iimulus amebocyte lysate chromogenic assay (LAL 
Assay; Whitaker Bioproducts Inc., Walkersville, MD), the endo- 
toxin content of the highest concentration of this preparation used 
for  our  studies  (51  #g/ml  in  HMEM/Pipes,  to  provide  30 
#g/kg/dose), was  13.1 EU/ml ("~1.5 ng/ml), whereas the value 
for the HMEM/Hpes alone was 2.3 EU/ml (0.27 ng/ml). Based 
on these values and the volume of the reagents injected (20 #1), 
the amounts of endotoxin that were administered in these prepara- 
tions were at least 30- to 200-fold less than that required to elicit 
significant inflammation when injected into the skin of mice (25). 
M/c~  Genetically mast cell-deficient  W/W ~ or SI/S~  t mice and 
the congenic normal (+/+) mice ([WB/ReJ-W/+  x  C57B1/6J- 
I4~/+]F~[W/WL  +/+], designated here WBB6F1[W/WL  +/+], 
and [WC/ReJ-SI/ +  x  C57B1/6J-SIa/ + ]F~[SI/SI  a,  +/+],  desig- 
nated  here WCB6Ft[$1/SI  d,  +/+])  were purchased  from  The 
Jackson Laboratory (Bar Harbor, ME). C57BL/6 mice were pur- 
chased from the Charles River Laboratories (Wilmington, MA). 
The skin of adult W/W ~ (26) or Sl/SI  a (27) mice contains <1.0% 
the number of dermal mast cells present in the skin of the con- 
genie normal (+/+) mice. All mice were used at 2-7 mo of age 
unless  stated otherwise. 
Measurement of Tissue Swelling and Assessment of  Mast Cell Activa- 
tion.  Ear swelling was determined by measurements of ear thick- 
ness with a micrometer before and at various  intervals  after the 
injection of rrSCF 164 or vehicle;  swelling  was  expressed  as  the 
increment (A) of thickness (postinjection value -  preinjection base- 
line value) in units of 10 -4 in (23,  24). 
In all experiments, tissue from the injection sites was obtained 
after the mice were killed by cervical dislocation and were processed 
for 1-/~m Epon-embedded, Giemsa-stained  sections (28, 29). Sec- 
tions were coded and then were examined by observers who were 
unaware of the identity of individual sections. The number of mast 
ceils per square millimeter of dermis in each biopsy specimen was 
determined as previously described (23, 24), and the mast cells were 
classified morphologically as exhibiting extensive  degranulation 
(50% of the cytoplasmic granules exhibiting fusion, staining alter- 
ations,  and/or extrusion from the cell), moderate degranulation 
(10-50% of the granules exhibiting altered or discharged),  or no 
significant degranulation ("none"; <10% of the granules exhibiting 
alternatives  (23,  24). 
Assessment of  SCFqnduced ~2~I-Fibrin  Deposition.  In most experi- 
ments, we assessed altered vascular permeability using a very senti- 
tire assay for detecting extravasation of lzSI-guinea pig fibrinogen 
(12sI-GPF) and deposition of crosslinked  12sI-fibrin (30,  31).  At 
20-30 rain before challenge with SCF, the mice were injected in- 
travenously with ~2-3  x  106 cpm of lzSI-GPF. The swelling re- 
sponses in SCF- and control-injected ears were measured with a 
micrometer 1 and 2 h after challenge as described above. The mice 
then received a mixture of anticoagulants and antifibrinolytic agents 
intravenously to impede clotting or fibrinolysis during specimen 
preparation: each mouse received 0.2 ml of a mixture containing 
80 U heparin, 20 #g D-phenyhlanyl-t-prolyl-L-arginine chloromethyl 
ketone, 2 #g e-aminocaproic acid, and 56 U trasylol, all in 0.15 M 
NaC1. Immediately thereafter, the mice were lightly anesthetized 
with ether, and a sample of retroorbital blood was obtained. These 
samples, which exhibited no clotting during an observation period 
of 3 h, were centrifuged at 10,000 g at room temperature to pre- 
pare platelet-poor plasma for radioactive counting. The mice were 
killed by cervical dislocation immediately after retroorbital bleeding, 
and both ears were amputated and trimmed. A small furl=thickness 
biopsy of each ear was fixed as described above for histologic studies. 
The rest of each ear was then promptly minced into fine fxagments in 
2-ml 0.01 M phosphate buffer (pH 7.5) containing a mixture of 
proteolytic inhibitors:  heparin (10 U/ml), D-phenylahnyl-t-arginlne 
chloromethyl ketone (5 mg/ml), EDTA (2 mg/ml), e-aminocaproic 
acid (0.1 M), trasylol (10 U/ml), 2 mM PMSF, 2 mM iodoacetate, 
and 2 mM N-ethylmaleimide. The minced ears were then extracted 
in the buffer by keeping the tubes for 18 h at 4~  Each tube was 
centrifuged (1,000 g  for 20 rain at 20~  and supernatant was 
decanted. The pellet containing the tissue  fragments was resus- 
pended vigorously in 2 ml of the same buffer and was centrifuged 
again,  as above. The supernatant was aspirated  and pooled with 
the earlier extract for radioactive counting as the "aqueous extract:' 
The pelleted tissue  fragments were suspended  in 2 ml of freshly 
prepared 3-M urea, extracted for 2 h at 37~  centrifuged (1,000 g 
for 20 min at 20~  and the urea-soluble supernatant and the urea- 
insoluble pellet counted for radioactivity in a Tm Analytic 1193 
gamma counter. *~SI-GPF--derived  species present in mouse tissues 
consist of a mixture of fibrinogen, fibrin, and fibrinogen-fibrin 
degradation products (31). The "urea-insoluble" residue consists 
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of crosslinked fibrin. 
Bone Marrow Transplantation of Mast Cell-deficient (W/IqP) Mice. 
Mast cell deficient W/I4  ~ mice received an injection of 2.0  x  107 
i.v. femoral bone marrow cells pooled from their congenic (+/+) 
littermates.  Kitamura et al.  (26)  demonstrated that  10 wk after 
they received such transplantation of congenic  +/+ bone marrow 
cells, the recipient W/W ~ mice had undergone correction of both 
their macrocytic anemia and their mast cell deficiency. 
Mast  Cell  Reconstitution  of Mast  Cell-deficient  W/I4  ~  Mice. 
W/W  ~ mice were repaired of their mast cell deficiency sdectively 
and locally by the injection of growth factor-dependent, BMCMC 
into one ear (23, 24, 31). We reported that IL,3-dependent BMCMC 
of WBB6F~-+/+  origin maintained in suspension culture repre- 
sent immature mast ceils that express certain phenotypic similari- 
ties to mucosal mast cells, but that upon injection into the skin 
(23,  24, 31, 32) of WBB6F1-W/W  ~ mice, these mast cell popula- 
tions gradually (over a 10-wk period) acquire multiple phenotypic 
characteristics  of the  mature  connective  tissue-type  mast  cells 
(CTMC) present in the dermis of normal mice. Moreover, injec- 
tion of BMCMC into one ear of W/I,W mice repairs the mast cell 
deficiency in that ear alone. The mice remain mast cell deficient 
at other cutaneous sites and in other organs, and remain anemic 
as well (23, 24, 31, 32).  Briefy, bone marrow cells from WBB6Ft 
+/+  mice were grown in vitro for 3-5 wk in concamvalin A-stimu- 
lated mouse spleen cell-conditioned medium until mast ceils rep- 
resented  >95%  of the  total ceils  as determined by neutral  red 
staining.  Mast  cells  (0.5  x  106) in  20  /zl  of DMEM  (Gibco 
l.aboratories, Grand Island, NY) were injected into the left ears 
and 20/~1 of medium alone into the right ears. The mice were used 
for experiments 10 wk after injection of mast cells. In each experi- 
ment, we confirmed histologically that local reconstitution of dermal 
mast ceil populations had occurred and determined that the W/W  ~ 
mice locally reconstituted with mast cells remained anemic. 
Induction of Cutaneous Mast Cells in W/W  ~ and Congenic  +/+ 
Mice by the Chronic Application  of PMA.  We previously showed 
that the chronic epicutaneous application of PMA to the skin of 
genetically mast cell-deficient  W/W ~ mice induces  the develop- 
ment  of mature  dermal  mast  cells  that  morphologically  and 
histochemically resemble the dermal CTMC of normal mice and 
that are fully competent to orchestrate IgE-dependent passive cu- 
taneous anaphylaxis responses (33). Moreover, these PMA-induced 
W/W v mast cell populations persist at the treated sites even after 
PMA treatment has been stopped to permit the inflammatory reac- 
tions at these sites  to wane (34).  For these experiments,  W/W ~ 
mice and congenic  +/+  mice received  5 #g of PMA in 5 #1 of 
acetone to the inner surface of the left ear and acetone alone to 
the inner surface of the right (control) ear, three times a week for 
6 wk. The mice received no treatment for an additional 16 d and 
then were used in an experiment. Some mice from both  W/W ~ 
and congenic  +/+  groups received E. coli--defived SCF (10 t.tg) 
into both ears,  whereas other mice from both groups received  a 
similar dilution of PBS in HMEM/PIPES into both ears. The latter 
groups represented controls for any possible effects of the chronic 
PMA  treatment  alone  on  cutaneous  vascular permeability.  Ear 
swelling measurements, assessment of P~I-fibrin deposition,  and 
histology were performed as described above.  To test the ability 
of W/W  ~ mast cells to orchestrate passive cutaneous anaphylaxis 
responses, reactions were elicited as previously described (31) by 
injecting a monoclonal anti-DNP IgE (35) or vehicle alone into 
the ears and then challenging the mice "~24 h later by injecting 
100/zg  of DNP human serum albumin (DNP~.~HSA)  (Sigma 
Chemical Co., St. Louis,  MO) intravenously in 0.1 ml of sterile 
0.9% NaC1 containing 1.0% Evans blue dye (Sigma Chemical Co.). 
The reactions were assessed 2 h after antigen challenge by visual- 
ization of the blue dye as well as by assessment of tissue swelling, 
12sI-fibrin deposition,  and histology, as noted above. 
StatisticalAnalysis.  The results of ear swelling assays, and differ- 
ences in mast cell counts in different groups of mice, were analyzed 
for statistical significance  (p <  0.05) by the unpaired Student's t 
test (two-tailed);  comparison of values in the left (challenged) versus 
right (control) ears of the same mice was performed using the paired 
Student's t test (two-tailed). Ratios of radioactivity in left (chal- 
lenged) versus fight (control) ears were analyzed by the Mann- 
Whitney U  test (two-tailed). The extent of mast cell activation 
(marked degranulation,  moderate degranulation, normal) was as- 
sessed using the X  2 test. Each experimental group contained four 
to five mice. All results are expressed as the mean  _+  SEM. 
Results 
SCF Induces  Cutaneous Inflammation  and Mast Cell Activa- 
tion  In  Viva  We first determined  whether  rrSCF 164 could 
induce mast cell activation and an acute inflammatory response 
when injected at doses similar to those that induce mast cell 
proliferation in vivo (2).  Fig.  1 shows that  all three forms 
of rrSCF 164 tested,  including  CHO-derived  (glycosylated) 
rrSCF1%  E.  coli-derived  (nonglycosylated)  rrSCF 164,  and 
PEG-rrSCF 164,  induced  the  rapid  development  of  tissue 
swelling  and  nsI-fibrin  deposition  when  injected  into  the 
skin  of normal mice at  30/zg/kg/site. 
We then  evaluated the effect of injecting  different  doses 
of E. coli-derived rrSCF 164 into the skin of C57BL/6  mice. 
rrSCF 164 induced significant lzsI-fibrin deposition (Fig.  2 A) 
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(A) Total nSI-GPF-derived cpm 2 h after injection of vat- 
ious preparations of rrSCF 164 (left ears, 30 #g/kgAite) or vehicle alone 
(right ears) into C57BL/6  mice. (B) Ear swelling (postinjection minus 
baseline values) determined in the same mice 1 and 2 h after injection. 
~  < 0.05 and *  ~  < 0.001 vs. value for contralateral vehicle-injected ears 
by the paired Student's t test (two-tailed). 
247  Wershil  et al. og 
-  -5 
0,7: 
30 
20 
r-- 
0  01 
NS 
0.1  1  10 
E CO11-SCF (pg /  kg /  site) 
30 
80]  []  SCF-tnjectedears 
~  []  Vehtcle-|nJected  ears 
6o 
40- 
m 
20- 
0 
0 01  0 1  1  10  30 
E coh-SCF  (pg /  kg /  site) 
Figure 2.  (,4)  Ratio of crosslinked t2Sl-fibrin-assodated cpm (urea- 
insoluble tzSI-cpm)  in left vs. right ears determined 2 h after injection of 
various doses of E. coli-rrSCF  t64 into left ears and vehicle alone into right 
ears. *p < 0.05 and **p < 0.01 for indicated comparisons by the Mann- 
Whitney U test (two-tailed).  All values for sites injected with rrSCF  TM 
at doses of ;~0.1/~g/kg/site are significantly greater (p < 0.01-0.001) than 
that at sites injected with 0.01 #g/kg/site. (B) Ear swelling in rrSCF 164- 
injected left ears vs. vehicle-injected right ears, determined 2 h after injec- 
tion in the same mice shown in A. **p < 0.01 vs. value in contralateral 
vehicle-injected ears by the paired Student's  t test (two-tailed). 
and tissue swelling (Fig. 2 B) in doses as low as 0.1 #g/kg 
(~140 fmol) per site.  When  the results were expressed as 
the  ratio  of the  crosslinked  t2sI-fibrin-associated  cpm  in 
rrSCFt64-challenged  as opposed to vehicle-injected  mice (Fig. 
2 A), the amount of 12sI-fibrin at rrSCF t64 injected sites was 
~21  times that  at control sites  at a dose of 10/zg/kg  and 
"~5 times that  at control sites  at a dose of 0.1/zg/kg. 
Histological analysis demonstrated extensive mast cell ac- 
tivation at the sites that had been injected with all three forms 
of rrSCF t64, but not  at control  sites  injected with  vehicle 
(Table 1). Moreover, the intradermal injection of various doses 
ofE. coli-SCF in the experiments reported in Fig. 2 induced 
a dose-dependent activation of dermal mast cells (Table  1). 
Mast cell activation was extensive at the higher doses tested 
(e.g., 75 _+ 2% and 73 +_ 10% extensively degranulated mast 
cells at sites injected with E. coli-SCF at 30 and 1.0/zg/kg/site, 
respectively).  However, even at doses at low as 0.1/~g/kgAite, 
activation  of  mast  cells  at  rrSCF t~a  injection  sites  was 
significantly greater than  that  at contralateral  control sites 
injected with vehicle alone. Comparison of these findings to 
the results of our previous study of the effects of substance 
P on dermal mast cell activation (24) indicates that rrSCF 164 
is at least 10 times more potent on a molar basis as a dermal 
mast cell activating  agent  than  is  substance P. 
Cutaneous Inflammation Induced by SCF is Mast Cell-Depen- 
dent.  To determine the extent to which the acute inflam- 
mation induced by intradermal rrSCF 164 is mast cell depen- 
dent, we injected rrSCF 164 into the skin of genetically mast 
cell-defirient mice and the congenic normal mice. We first 
tested  W/kV  v mice  and  their  normal  (+/+)  littermates. 
Fig. 3 A  shows that injection of E. coli-rrSCF t64 at 30/zg/ 
kgAite produced neither significant tissue swelling nor sig- 
nificant  t2sI-fibrin  deposition  in  the  skin  of W/W ~ mice, 
whereas the identically challenged normal littermates  exhibited 
the expected inflammatory responses. In other experiments, 
W/W v  mice  gave  no  significant  response  to  doses  of 
rrSCF t64 as high  as  100 Izg/kg/site  (data not  shown). 
The results obtained with W/W ~ mice are consistent with 
the possibility that mast cells are required for the proinflamma- 
tory effects of rrSCF t64. However, these experiments are also 
consistent  with  a  second  possibility:  rrSCFt+4-induced 
inflammation is mast cell independent but requires an intact 
c-kit  receptor.  To  address  this  possibility,  we  injected 
rrSCF t64  into  genetically  mast  cell-deficient  SI/SI  ~ mice. 
These animals express a normal c-kit receptor, but virtually 
lack cutaneous mast cells.  As shown in Fig.  3 B,  rrSCF  164 
(30/~g/kgAite) produced no detectable inflammation when 
injected intradermally into the skin of SI/SI  a mice. By con- 
trast,  the normal  (+/+) littermates gave a strong response 
(Fig.  3 B). The failure of even high doses of rrSCF 164 to in- 
duce any detectable augmented vascular permeability, tissue 
swelling,  or t2sI-fibrin  deposition in  W/W v or SI/S!  d mice 
indicates that  it is the lack of mast cells in these mutants, 
not abnormalities in the c-kit receptor per se, that is respon- 
sible for the animals' unresponsiveness to the proinflamma- 
tory effects of rrSCF 164. This conclusion is supported fur- 
ther  by  the  demonstration  that  reconstitution  of  W/W" 
mice with mast cells of congenic  +/+  origin permits these 
mice to develop an inflammatory response to intradermal chal- 
lenge with rrSCF t64 (see below). 
Proinflammator),  Effects  of Intradermal  Injection of rrSCF  ''+ 
Require Mast Cells with a Functionally Active c-kit Receptor.  To 
evaluate whether  the  proinflammatory  effects of rrSCF t64 
reflected a c-kit-dependent  action of the cytokine on mast 
cells,  we  evaluated  the  effects  of injecting  rrSCF 164  (10 
#g/kg site), or vehicle,  into  W/W ~ mice containing either 
normal (+/+) mast cells or mast cells of W/W ~ origin that 
express a defective c-kit receptor.  Fig. 4 shows that  W/W ~ 
mice that contained adoptively transferred dermal mast cell 
populations of +/+  origin developed tissue swelling and ex- 
tensive deposition of lzsI-fibrin at sites of rrSCF t~ injection. 
Note that rrSCF ~4 induced an inflammatory response only 
in  the left ears  of these  W/W v mice,  i.e.,  in  those ears in 
which dermal mast cells had been selectively reconstituted 
by local  injection  of BMCMC  of WBB6Ft-+/+  origin. 
The number of mast cells in these ears was 34  _+  3/mm 2 
of dermis, of which 34 +  4% or 34 _+ 4% exhibited exten- 
sive or moderate &granulation, respectively.  By contrast, the 
mast  cell-deficient  right  ears  of these same mice (0 mast 
cells/mm z)  developed little  or  no  reaction  in  response  to 
248  Rat c-hit Ligand Induces Mouse Mast Cell Activation Table  1.  Extent of Dermal Mast  Cell Activation in the Skin of C57BL/6 Mice Injected with rrSCF  16+ and Examined 2  h Later 
Mast cell degranulation 
p Value: 
Agent  rrSCF  lu  Ear  None  Moderate  Extensive  L vs. R 
/.~g/kg  fro  fro  ~g 
CHO-SCF  30  L  12  _+  2  20  _+  4  68  +  2  /~ <~ 0.01 
Vehicle  0  R  76  _+  7  13  _+  3  10  _+  4 
Polyethylene glycol-SCF  30  L  7  +  2  11  _+  1  82  _+  1  p <  0.01 
Vehicle  0  R  95  _+  2  5  _+  2  0 
E.  coli-SCF  30  L  8  _+  2  18  _+  3  75  _+  2  p < 0.01 
Vehicle  0  R  87  _+  4  8  _+  2  5 _+  2 
E.  coli-SCF  1  L  14  _+  6  13  _+  5  73  _+  10  p <  0.01 
Vehicle  0  R  87  _+  2  10  +  1  3  _+  2 
E.  coli-SCF  0.1  L  62  _+  2  28  _+  6  10  _+  3  /~ <  0.01 
Vehicle  0  R  97  _+  2  2  _+  1  1 _+  1 
E.  coli-SCF  0.01  L  90  _+  2  7 _+  2  3  +  1  NS 
Vehicle  0  R  97  _+  1  3  _+  1  0 
These data are from the same experiments depicted in Figs. 1 and 2. 
NS, not significant  (p > 0.05). 
rrSCF  164 injection. We also injected rrSCF  1~ (10/zg/kg/site) 
into the ears of W/W ~ mice that had undergone repair of 
their mast cell deficiency as a result of intravenous injection 
of bone marrow cells of WBB6Ft-+/+  origin. The extent 
of mast cell degranulation, and the inflammatory responses, 
observed in these mice were similar in magnitude to those 
in identically challenged  +/+  mice (data not shown). 
In contrast to  W/W ~ mice containing adoptively trans- 
ferred mast cell  populations of  +/+  origin,  W/W ~ mice 
that contained PMA-induced dermal mast cells of W/W ~ 
origin developed no significant tissue swelling or lZSI-fibrin 
deposition at sites injected with 10/tg/kg of rrSCF  ~64 (Fig. 
5 A). This finding reflected neither a general unresponsive- 
ness of the  W/W ~ dermal mast cells nor a suppression of 
mast cell reactivity at sites of PMA treatment. Thus, W/W ~ 
mast cells at sites of PMA treatment were able to orchestrate 
passive cutaneous anaphylaxis reactions which were similar 
in magnitude to those observed in the P/VIA-treated ears of 
the congenic  +/+  mice (p >  0.05 by the Student's t test, 
two-tailed) (Fig. 5 C). Moreover, in WBB6FI-+/+  mice, 
sites  treated chronically with PMA developed amounts of 
rrSCFt64-induced  (Fig.  5 B),  or IgE and antigen-induced 
(Fig.  5 C) tissue swelling and a2sI-fibrin deposition that ac- 
tually exceeded those recorded at identically challenged con- 
tralateral sites that had been treated with acetone alone. This 
result indicates that chronic PMA treatment does not reduce, 
and actually appears to enhance, mast cell-dependent responses 
to  challenge with either rrSCF  164  or  IgE and antigen in 
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normal (+/+) mice. Furthermore, comparison of the results 
obtained at PMA-treated or acetone-treated sites that had been 
challenged with vehicle indicated that chronic treatment with 
PMA did not significantly augment baseline  levels of vas- 
cular permeability at these sites either in W/W v mice (Fig. 
5 A) or in  +/+  mice (Fig.  5 B).  Fig. 5, A  and B report 
the results of one of two independent sets of experiments, 
both of which gave similar results. 
Histological analysis  of the injection sites  of the  mice 
reported in Fig. 5 confirmed that mast cells had developed 
at sites of PMA treatment in W/W v mice, but not at con- 
tralateral control sites treated with acetone alone,  and also 
showed that PMA treatment increased  numbers of dermal 
mast cells in +/+ mice (Table 2). Dermal mast cells of +/+ 
origin in the PMA- or acetone-treated skin of +/+  animals 
exhibited extensive degranulation when examined 2 h after 
challenge with rrSCF  le4 (Table 2). By contrast, little or no 
mast cell activation was exhibited at sites of rrSCF 164 chal- 
lenge in the PMA-treated skin of W/W ~ mice (Table 2). In- 
deed, the extent of mast cell activation observed at sites of 
rrSCF t64 injection in the PMA-treated skin of W/W ~ mice 
was not significantly different than that at sites of vehicle 
injection (p ~> 0.05 by the X  2 test). However, extensive de- 
granulation of W/W ~ dermal mast cells was observed at sites 
of passive  cutaneous  anaphylaxis  (Table  2).  This  result 
confirmed our previous work (33)  indicating that  W/W ~ 
mast cells can degranulate in response to challenge with IgE 
and antigen. m 
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Figure 3.  Crosstinked 12sI-fibrin-associated cpm (urea- 
insoluble z25I-cpm) (filled bars) and ear swelling (open bars) 
determined 2  h  after  injection of E.  coli-rrSCF 164 (30 
/~g/kg/site, left ears) or vehicle alone (fight ears) in (A) 
genetically mast cell-deficient W/W v vs. congenic normal 
(+/+) mice and (B) genetically mast cell-deficient  SI/SY 
vs. congenic normal (+/+) mice. **'p < 0.001 vs. values 
for contralateral vehicle-injected ears by paired Student's 
t test (two-tailed). 
Discussion 
rrSCF  t64 induced dermal mast cell activation and a mast 
cell-dependent  acute inflammatory response when injected 
intradermaUy at doses as low as 140 fmolsAite. On a molar 
basis, rrSCF  164 thus is at least 10-fold more potent as an ac- 
tivator of mouse dermal mast ceils than is the classical CTMC 
agonist substance P (24). Our results indicate that the ability 
of rrSCF 164 to induce augmented cutaneous vascular perme- 
ability, local fibrin deposition, and tissue swelling were pri- 
marily, and perhaps entirely, mast cell dependent. Injection 
of rrSCF 164 into either  W/W  v or SI/SY mast cell-deficient 
mice was without significant effect, even when the cytokine 
was  injected  at  a  dose  1,000  times  that  which  induced 
significant mast cell activation and acute inflammation in +/+ 
mice.  By contrast,  rrSCF 164  was  able  to  induce  an  acute 
inflammatory response when injected into the skin of W/W  ~ 
mice repaired of their cutaneous mast cell defidency by the 
adoptive transfer of bone marrow ceils or BMCMC derived 
from the congenic normal  (+/+)  mice. 
These observations posed at least two questions. First, by 
what mechanism does intradermal injection of rrSCF 164 in- 
duce mast cell activation? The cytokine could either activate 
mast cells directly or indirectly, via effects on other cell popu- 
lations or mediators.  And direct effects on the mast cell el- 
ther could be mediated by an interaction between rrSCF  164 
and the c-kit receptor or could reflect c-kit receptor-indepen- 
dent  mechanisms.  Our  experiments  with  W/W  v  mice 
strongly suggest that the ability of rrSCF 164 to induce mast 
cell activation is a direct effect of the cytokine and requires 
a functionally active c-kit receptor. Thus,  rrSCF  x64 induced 
extensive activation of dermal mast cells, as well as the rapid 
development  of fibrin  deposition  and  tissue  swelling,  in 
W/W  ~ mice  whose  skin  contained  adoptively  transferred 
populations  of mast cells  derived from the congenic  +/+ 
mice.  by contrast,  injection  of rrSCF 164 into  the  skin  of 
W/W  ~ mice that contained mast cells of W/W"  origin in- 
duced neither mast cell activation nor an inflammatory re- 
sponse. Both our previous studies (33, 34) and the present 
experiments  showed that  the  dermal  mast cells  of W/W  ~ 
origin that develop as a result of chronic PMA treatment of 
the skin of W/W  v mice are fully competent to orchestrate 
IgE-dependent passive cutaneous anaphylaxis responses. The 
failure of W/W  ~ dermal mast cells to respond to challenge 
with rrSCF  t64, therefore, does not reflect a general inability 
of these cells to degranulate and release mediators upon ap- 
propriate stimulation.  Most probably, the unresponsiveness 
of W/W  ~ dermal mast cells to rrSCF 164 reflects  the surface 
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Figure 4.  Crosslinked :~I-fibrin-associated cpm (urea-insoluble lZSl- 
cpm) (filled bars) and ear sweUing (open bars) determined 2 h after injection 
orE. coli-rrSCF ~4 into both the mast cell-reconstituted left ears and the 
mast cell-defident right ears of W/W  ~ mice that underwent selective  local 
reconsti~tion of skin mast cells by injection ofBMCMC ofcongenic +/+ 
origin into the left ear 10 wk prior to the injection of rrSCF :64. *p < 
0.05 and ***p < 0.001 vs. values for the contralateral mast cell-deficient 
ears by the paired Student's t test (two-tailed). 
expression by these ceils of c-hit receptors with markedly im- 
paired  tyrosine  kinase  activity (36). 
In contrast  to its potency as an activator of dermal mast 
cells in vivo, rrSCF 164 is a  relatively weak  agonist  of mast 
cell activation in vitro (21). Certain populations of in vitro-de- 
rived mast cells exhibited modest activation in response to 
challenge  with  rrSCF 164, but  these  effects  were  observed 
only at concentrations  of rrSCF 164 of 50-500  ng/ml,  levels 
10- to 100-fold higher than those necessary to induce prolifer- 
ation of these cells (21). Moreover, rrSCF ;~4 did not induce 
significant  [3H]SHT release from freshly purified mouse or 
rat peritoneal mast cells, even when tested at concentrations 
of up  to  5.0 #g/ml  (21).  Although  the  results  of in  vitro 
and in vivo experiments should be compared cautiously, 5.0 
/~g/ml  represents  an  *30-fold  higher  concentration  of 
rrSCF 164 than the lowest concentration  necessary to induce 
significant dermal mast cell degranulation and inflammation 
when injected intradermaUy in vivo. There are at least two 
possible explanations for the apparent differences in the re- 
sponsiveness of mast ceils to challenge with rrSCF ;~4 in vitro 
or in vivo. First,  optimal responsiveness to ITSCF 164 may re- 
quire a cofactor that is present  in the  skin in vivo but  not 
in the conditions  tested in vitro.  Second,  responsiveness  to 
rrSCF ;64 as a stimulus of mast cell mediator release may vary 
according to mast ceil phenotype. Although dermal mast ceils 
and peritoneal  mast ceils are both regarded  as examples of 
CTMC  in routine rodents (reviewed in reference 22),  these 
populations differ in size and morphometric characteristics 
of cytoplasmic granules  (37).  They may also vary in  their 
responsiveness  to rrSCF 164, whether  because of differences 
in the amounts of c-kit ligand expressed endogenously in the 
skin as opposed to the peritoneal cavity or because of other 
factors. 
The second major question prompted by our observations 
concerns  the biological relevance of the findings.  We have 
reported that rrSCF ;~4 can induce c-k/t-dependent mast ceil 
proliferation in vitro (3) and in vivo (2),  and that rrSCF ;~ 
also can promote maturation of immature mast ceils, as judged 
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Figure 5.  Cmsslin~l 1~I-~brin-assodated ~m (urea-~nsoluble  1251- 
cpm) (filled bars) and ear swelling (open bars) determined 2 h after injection 
orE. coli-rrSCF 1~ (10 #g/kg/site)  or vehicle alone (A and B), or 2 h after 
challenge for induction of a passive cutaneous anapbyhxis reaction (C). 
In each ~periment (A-C), the left ears had been treated repeatedly with 
PMA in acetone, and the right ears with acetone alone (as a control), to 
induce local development of W/W  ~ dermal mast cells in the skin of PMA- 
treated W/W" mice (A and C), and to increase numbers of +/+  mast 
cells locally at PMA-treated sites in the skin of congenic +/+  mice (B 
and C) (see Materials and Methods). 16 d after cessation of PMA/acetone 
treatment, some mice were challenged in both ears by intradermal injec- 
tion of rrSCF 1~ (A and B), other mice were challenged in both ears by 
injection of vehicle alone (A and B), and other mice (C) were challenged 
in both ears by injection of a monoclonal anti-DNP IgE, followed, 24 h 
hter, by intravenous injection of spedfic antigen (DNP30-~-ISA). (A) 
W/W" mice do not respond to challenge with rrSCF 164, either in PMA- 
treated ears or acetone-treated ears. (B) +/+ mice develop ia{hmmatory 
reactions in response to rrSCF 1~ (*p < 0.05, or ***p < 0.001 vs. values 
for identically pretreated, but vehicle-challenged  ears) and these reactions 
are significantly more intense in PMA-treated ears than in acetone-treated 
skin (T  F < 0.05 vs. values for rrSCFl~4-injected, acetone-treated ears), (C) 
+/+  mice develop passive cutaneous anaphylaxis reactions that are sig- 
nificantly more intense in PMA-treated ears than in acetone-treated ears; 
W/W" mice develop intense passive cutaneous anaphylaxis reactions in 
PMA-treated ears, but not in acetone-treated ears ('r~  < 0.05, 'rip < 0.01, 
or l''r'rp  <  0.001, respectively, vs. values in identically challenged con- 
tralateral acetone-treated ears). Table  2.  Numbers of Dermal Mast Cells, and Extent of Dermal Mast Cell Activation,  in the Skin of Mice Containing W/W  v or 
Congenic  +/+  Mast Cells 2  h After Intradermal Injection of E. coli-SCF (lO /~g/kg/site) or Vehicle Alone,  or 2 h After Challenge 
to Induce a Passive Cutaneous Anaphylaxis  Reaction 
Mast cell degranulation 
Mouse genotype  Ear  Treatment  Mast cell genotype  Challenge  Mast cells  None  Moderate  Extensive 
WBB6F1-W/W  v 
WBB6F~- + / + 
n/mm 2 dermis  ~  9~ 
L  PMA  WBB6F1-W/W  ~  SCF  36  +_  10  82  _+  2  16  +  3  1 -+  1 
K  Acetone  None  SCF  0.2  -+ 0.2  -  -  - 
L  PMA  WBB6FI-W/W  v  Vehicle  43  _+  5  85  _+  5  12  _+  3  3  _+  2 
K  Acetone  None  Vehicle  0  -  -  - 
L  PMA  WBB6FI-W/W  ~  IgE/DNP-HSA  24  -+ 3  0  6 -+  3  94  +_  3 
R  Acetone  None  IgE/DNP-HSA  0  -  -  - 
L  PMA  WBB6F1-+/+  SCF  111  ,+  15  4  .+  1  24  +  4  72  ,+  4 (NS) 
K  Acetone  WBB6F1-+/+  SCF  78  .+  12  8 +_  2  25  ,+  3  65  ,+  3 
L  PMA  WBB6Ft-+/+  Vehicle  216  ,+  21  89  +_  2  8 .+  1  3  +  1 (NS) 
K  Acetone  WBB6F1-+/+  Vehicle  107  ,+  15  82  ,+  3  13  +  3  4  +_  2 
L  PMA  WBB6F~-+/+  IgE/DNP-HSA  116  _+  15  10  _+  3  16  ,+  2  74  +_  2 (NS) 
K  Acetone  WBB6F~-+/+  IgE/DNP-HSA  63  +_  7  22  +_  6  28  _+  3  50  _+  6 
These data are from the same experiments depicted in Fig. 5. 
NS, not significant  (p > 0.05) when compared to values for contralateral 
by several criteria including histamine content and pattern 
of proteoglycan synthesis in vitro (3) and histochemistry and 
pattern of protease synthesis in vivo (2). Taken together with 
the profound mast cell deficiency expressed by both W/W V 
and SI/SI  d mice (1,  12,  26,  27),  these findings leave little 
doubt that interactions between the c-kit receptor and its ligand 
are essential  for normal mast cell development. 
But it is more difficult to form a firm conclusion about 
the physiological importance of SCF as a stimulus of mast 
cell mediator release. Using different approaches, two groups 
recently showed that activation of the c-kit receptor kinase 
by ligand binding resulted in a pattern of intracellular signal 
transduction that included binding and complex formation 
between the c-kit receptor and phosphatidylinositol Y-kinase 
(38, 39). However, these reports did not determine whether 
such c-kit receptor-dependent signal transduction resulted in 
mast cell mediator release. The data presented here indicate 
that rrSCF  164 can induce c-kit receptor-dependent mast cell 
activation and mediator release. In addition to demonstrating 
that mast cell activation via the c-kit receptor results in the 
development of a mast cell-dependent inflammatory  response, 
our fndings represent, to our knowledge, the first evidence 
that administration of the c-kit ligand in vivo can stimulate 
the functional activation of any cell type that expresses the 
c-kit receptor. 
However, normal tissues do not ordinarily exhibit significant 
mast cell degranulation, or express inflammatory responses, 
without some sort of provocation. If interactions between 
acetone-treated ears by the X  2 test. 
the c-kit receptor and its ligand importantly contribute to 
the maintenance of mast cell populations in normal tissues, 
as seems likely, then such interactions ordinarily must not 
result in sufficient mast cell activation to induce a perceptible 
inflammatory response.  Several factors may account for the 
lack of detectable inflammation due to c-kit receptor-depen- 
dent mast cell activation in normal tissues. C-kit ligands exist 
in cell membrane-associated forms (9, 40, 41) and in soluble 
forms, such as that represented by rrSCF  164, which consist 
of the first  164 or 165 amino acids of the extraceUular do- 
main (4-6, 9,  10, 41). Although both forms of the ligand 
are biologically active with respect to effects on proliferation 
(9, 41), it is possible  that soluble and membrane-associated 
forms of SCF may differ in their ability to induce mast cell 
degranulation. Moreover,  no information is available con- 
cerning the levels of any forms of the c-kit ligand that are 
present in normal tissues. Nevertheless, the lack of significant 
mast cell degranulation in normal tissues would indicate that 
physiologic interactions between c-kit receptors expressed by 
mast cells and endogenous forms of the c-kit ligand do not 
generally result in extensive  mast cell degranulation. 
On the other hand, the possibility cannot be ruled out 
that low levels of mast cell mediator release induced by c-kit 
receptor-dependent mast cell activation may have a role in 
both the development and function of this cell type. Activa- 
tion of mouse mast cells generated in vitro, via the Fc~KI 
or other mechanisms, induces the cells to develop increased 
levels of mKNA for several cytokines and/or to secrete the 
252  Rat c-kit Ligand Induces Mouse Mast Cell Activation products (42-45). Some of these cytokines, such as II.-3 and 
11.-4, can promote or augment mast cell proliferation, whereas 
others, such as granulocyte/macrophage CSF and IFN-3,, can 
suppress mast cell proliferation (reviewed in references 1, 22, 
46, and 47).  Recently, Razin et al.  (48) reported evidence 
that both BMCMC and mouse peritoneal mast cells devel- 
oped increased levels of mRNA for IL-3 after establishing con- 
tact with 3T3 fibroblasts in vitro. Several lines of evidence 
indicate that the ability of 3T3 fibroblasts to induce mouse 
mast cell proliferation and maturation requires an interaction 
between a c-kit receptor ligand expressed by the 3T3 cells 
and functionally active c-kit receptors expressed by the mast 
cells (reviewed in references 1-3, and 12). Taken together with 
the findings presented here, these observations raise the pos- 
sibility that one of the mechanisms by which SCF influences 
mast cell development is to induce mast cells to produce other 
cytokines with  autocrine  effects on mast cell proliferation 
and/or  maturation. 
In addition,  there has been a long history of speculation 
that  one "physiological" role of the mast cell is to release 
constitutively very low levels of the same mediators which, 
when released rapidly in larger quantities, result in the devel- 
opment of an inflammatory response (reviewed in reference 
49). Although our data by no means prove that physiolog- 
ical interactions between the c-k/t receptor and its endoge- 
nous ligands actually result in low levels of mast cell medi- 
ator  release  in  normal  tissues,  they  nevertheless  can  be 
considered compatible with this hypothesis. Furthermore, our 
findings suggest that conditions that result in high local con- 
centrations of soluble c-kit ligand,  whether of endogenous 
or exogenous origin, may be associated with significant mast 
call activation in routine rodents. It will be important to de- 
termine whether the same is true for human mast cells, since 
this information  will dearly influence the development of 
plans  for any clinical  applications  of this cytokine. 
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